TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
Brief Summary: The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin.

The data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.


Options:
A: Arm Label: Empagliflozin Arm; Type: OTHER; Interventions: Drug: Empagliflozin 10 mg | Intervention Type: DRUG; Name: Empagliflozin 10 mg; Assigned to Arm(s): Empagliflozin Arm
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Canagliflozin (JNJ-28431754) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 100 mg | Arm Label: Canagliflozin (JNJ-28431754) 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 100 mg | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 300 mg
C: Arm Label: Vildagliptin, 50 mg, peroral; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vildagliptin | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Vildagliptin; Assigned to Arm(s): Vildagliptin, 50 mg, peroral
D: Arm Label: 1.5 mg Dulaglutide; Type: EXPERIMENTAL; Interventions: Drug: Dulaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dulaglutide; Assigned to Arm(s): 1.5 mg Dulaglutide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus
Brief Summary: The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac events (MACE). Other objectives include evaluating the overall safety, tolerability, and effectiveness of canagliflozin.

The data from this study will be combined with the data from CANVAS-R study (Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects with T2DM, NCT01989754) in a pre-specified integrated analysis of CV safety outcomes to satisfy US FDA post-marketing requirements for canagliflozin.


Options:
A: Arm Label: linagliptin; Type: EXPERIMENTAL; Interventions: Drug: linagliptin, Drug: glimepiride placebo | Arm Label: glimepiride 1-4 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: linagliptin placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: linagliptin placebo; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: glimepiride placebo; Assigned to Arm(s): linagliptin
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Canagliflozin (JNJ-28431754) 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 100 mg | Arm Label: Canagliflozin (JNJ-28431754) 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754) 300 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 100 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 100 mg | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754) 300 mg; Assigned to Arm(s): Canagliflozin (JNJ-28431754) 300 mg
C: Arm Label: BI 1356 5mg, once daily; Type: EXPERIMENTAL; Interventions: Drug: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg, Drug: BI 1356 | Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo identical to BI 1356 5mg, Drug: Glimepiride | Intervention Type: DRUG; Name: Placebo identical to BI 1356 5mg; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 5mg, once daily | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride
D: Arm Label: Oral semaglutide; Type: EXPERIMENTAL; Interventions: Drug: semaglutide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: semaglutide; Assigned to Arm(s): Oral semaglutide | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of a Personal Health Record to Improve Colorectal Cancer Screening
Brief Summary: RATIONALE: Use of a web-based risk assessment tool may help improve screening rates for colorectal cancer.

PURPOSE: This randomized clinical trial is studying personal electronic health records to see how well they work in improving screening rates for colorectal cancer.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Other: video | Intervention Type: OTHER; Name: video; Assigned to Arm(s): 2
B: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A
C: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: CHOICE decision aid | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: YourMeds patient education program | Intervention Type: BEHAVIORAL; Name: CHOICE decision aid; Assigned to Arm(s): Intervention group | Intervention Type: BEHAVIORAL; Name: YourMeds patient education program; Assigned to Arm(s): Placebo group
D: Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fecal occult blood test; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of a Personal Health Record to Improve Colorectal Cancer Screening
Brief Summary: RATIONALE: Use of a web-based risk assessment tool may help improve screening rates for colorectal cancer.

PURPOSE: This randomized clinical trial is studying personal electronic health records to see how well they work in improving screening rates for colorectal cancer.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: CDS for psychotropic drug management | Intervention Type: DEVICE; Name: CDS for psychotropic drug management; Assigned to Arm(s): 2
B: Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fecal occult blood test; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Fall Prevention Tool Kit prototype using a randomized design | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Fall Prevention Tool Kit prototype using a randomized design; Assigned to Arm(s): 1
D: Arm Label: Receive CDS intervention; Type: EXPERIMENTAL; Interventions: Other: MAPLE | Arm Label: No CDS intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MAPLE; Assigned to Arm(s): Receive CDS intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Use of a Personal Health Record to Improve Colorectal Cancer Screening
Brief Summary: RATIONALE: Use of a web-based risk assessment tool may help improve screening rates for colorectal cancer.

PURPOSE: This randomized clinical trial is studying personal electronic health records to see how well they work in improving screening rates for colorectal cancer.


Options:
A: Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fecal occult blood test; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A
B: Arm Label: Standard tablet computer; Type: EXPERIMENTAL; Interventions: Other: Standard tablet computer | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Enhanced tablet computer; Type: EXPERIMENTAL; Interventions: Other: Enhanced tablet computer | Intervention Type: OTHER; Name: Standard tablet computer; Assigned to Arm(s): Standard tablet computer | Intervention Type: OTHER; Name: Enhanced tablet computer; Assigned to Arm(s): Enhanced tablet computer
C: Intervention Type: BEHAVIORAL; Name: Internet co-management module; Assigned to Arm(s): N/A
D: Arm Label: Integrated Cessation Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tobacco Treatment | Intervention Type: BEHAVIORAL; Name: Tobacco Treatment; Assigned to Arm(s): Integrated Cessation Counseling, Usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24 Week Multi-center, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study of AIN457 Versus Placebo for Maintaining Uveitis Suppression When Reducing Systemic Immunosuppression in Patients With Quiescent, Non-infectious Intermediate, Posterior or Panuveitis.
Brief Summary: This study will assess the safety and efficacy of AIN457 as adjunctive therapy for the treatment of intermediate uveitis, posterior uveitis, or panuveitis requiring systemic immunosuppression.


Options:
A: Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: Prednisone | Arm Label: Mycophenolate Mofetil; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil, Drug: Prednisone | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Mofetil | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Methotrexate, Mycophenolate Mofetil
B: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate mofetil | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil
C: Arm Label: AIN457 300mg s.c every 2 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457 300mg s.c. every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457 150mg s.c every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Placebo s.c every 2 weeks; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c every 2 weeks | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 150mg s.c every 4 weeks | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c. every 4 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c every 2 weeks
D: Arm Label: AIN457 300mg s.c weekly for 3 weeks; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 300mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 150mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: Placebo s.c weekly for 3 weeks; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c weekly for 3 weeks | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c at baseline and Week 2 | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 150mg s.c at baseline and Week 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c weekly for 3 weeks

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Self-monitoring of Oral antiCoagulant therApy by the PatiEnts
Brief Summary: The purpose of this study is to determine whether self-management of oral anticoagulation therapy with warfarin has an effect on patient's quality of life following a specific training program led by pharmacists.


Options:
A: Arm Label: Pharmaceutical care; Type: EXPERIMENTAL; Interventions: Other: Pharmaceutical care | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Pharmaceutical care; Assigned to Arm(s): Pharmaceutical care
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management
C: Arm Label: Pharmacist intervention; Type: EXPERIMENTAL; Interventions: Other: Pharmacist based QI program | Arm Label: Control - usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: OTHER; Name: Pharmacist based QI program; Assigned to Arm(s): Pharmacist intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Control - usual care
D: Arm Label: Patient-centred tailored intervention; Type: EXPERIMENTAL; Interventions: Other: Medicines Advice Service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Medicines Advice Service; Assigned to Arm(s): Patient-centred tailored intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Self-monitoring of Oral antiCoagulant therApy by the PatiEnts
Brief Summary: The purpose of this study is to determine whether self-management of oral anticoagulation therapy with warfarin has an effect on patient's quality of life following a specific training program led by pharmacists.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aspirin / Clopidogrel, Atorvastatin / Simvastatin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asprin / Clopidogrel, Atorvastatin / Simvastatin | Intervention Type: DRUG; Name: Aspirin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asprin / Clopidogrel, Atorvastatin / Simvastatin; Assigned to Arm(s): 2
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management
C: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: apixaban | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: apixaban; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Self-monitoring of Oral antiCoagulant therApy by the PatiEnts
Brief Summary: The purpose of this study is to determine whether self-management of oral anticoagulation therapy with warfarin has an effect on patient's quality of life following a specific training program led by pharmacists.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: Other: Case Management | Arm Label: Case Management; Type: EXPERIMENTAL; Interventions: Other: Case Management | Intervention Type: OTHER; Name: Case Management; Assigned to Arm(s): Case Management, Usual Care
B: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Monitoring by an HIV-trained medical doctor, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Monitoring by an HIV-trained primary care nurse, Drug: Efavirenz, Drug: Lamivudine, Drug: Lopinavir/Ritonavir, Drug: Nevirapine, Drug: Stavudine | Intervention Type: BEHAVIORAL; Name: Monitoring by an HIV-trained medical doctor; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Monitoring by an HIV-trained primary care nurse; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Lamivudine; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Lopinavir/Ritonavir; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Stavudine; Assigned to Arm(s): A, B
D: Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Enhanced pharmacist care; Type: EXPERIMENTAL; Interventions: Other: Enhanced pharmacist care | Intervention Type: OTHER; Name: Enhanced pharmacist care; Assigned to Arm(s): Enhanced pharmacist care | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Self-monitoring of Oral antiCoagulant therApy by the PatiEnts
Brief Summary: The purpose of this study is to determine whether self-management of oral anticoagulation therapy with warfarin has an effect on patient's quality of life following a specific training program led by pharmacists.


Options:
A: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 1mg, Drug: warfarin 5mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin
B: Arm Label: Dabigatran etexilate; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate low dose, Drug: dabigatran etexilate intermediate dose, Drug: dabigatran etexilate high dose | Arm Label: warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin 5mg, Drug: warfarin 1mg, Drug: warfarin 3mg | Intervention Type: DRUG; Name: dabigatran etexilate low dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 5mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate intermediate dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 1mg; Assigned to Arm(s): warfarin | Intervention Type: DRUG; Name: dabigatran etexilate high dose; Assigned to Arm(s): Dabigatran etexilate | Intervention Type: DRUG; Name: warfarin 3mg; Assigned to Arm(s): warfarin
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Self-management; Type: EXPERIMENTAL; Interventions: Other: Self-monitoring and adjustment of oral anticoagulation | Intervention Type: OTHER; Name: Self-monitoring and adjustment of oral anticoagulation; Assigned to Arm(s): Self-management
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Weekly patient self-testing of prothrombin time | Arm Label: Arm 2; Type: OTHER; Interventions: Other: High quality anticoagulation management (HQACM) with conventional monthly testing | Intervention Type: PROCEDURE; Name: Weekly patient self-testing of prothrombin time; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: High quality anticoagulation management (HQACM) with conventional monthly testing; Assigned to Arm(s): Arm 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of the Muscle Strength and Motor Ability in Children With Spinal Muscle Atrophy Type II and III Treated With Valproic Acid
Brief Summary: The purpose of this study is to determine if the treatment with valproic acid can increase the muscle strength and motor ability of children with spinal muscular atrophy.


Options:
A: Arm Label: Cohort 1a; Type: PLACEBO_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine, Drug: Placebo | Arm Label: Cohort 1b; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valproic Acid and Levocarnitine | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Valproic Acid and Levocarnitine | Intervention Type: DRUG; Name: Valproic Acid and Levocarnitine; Assigned to Arm(s): Cohort 1a, Cohort 1b, Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1a
B: Arm Label: Nusinersen; Type: EXPERIMENTAL; Interventions: Drug: Nusinersen | Intervention Type: DRUG; Name: Nusinersen; Assigned to Arm(s): Nusinersen
C: Intervention Type: DRUG; Name: Valproic Acid; Assigned to Arm(s): N/A
D: N/A

Answer: D